Patents by Inventor Xuejun Karl Liu

Xuejun Karl Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11427530
    Abstract: The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 30, 2022
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: Daniel Levin, Peter Leeming, Emerich Eisenreich, Xuejun Karl Liu
  • Publication number: 20210276942
    Abstract: The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.
    Type: Application
    Filed: February 11, 2019
    Publication date: September 9, 2021
    Inventors: Daniel LEVIN, Peter LEEMING, Emerich EISENREICH, Xuejun Karl LIU
  • Patent number: 10519109
    Abstract: Novel glycopyrronium fatty acid salts have been developed. Bi-phasic reaction conditions enable the desired counterion exchange reactions between glycopyrronium bromide and fatty acid salts of alkali metals and alkaline earth metals in methods to form glycopyrronium fatty acid salts. In preferred embodiments, an excess of the free fatty acid in the reaction mixture stabilizes the glycopyrronium fatty acid salt and reduces the formation of the impurity, Acid A. In some preferred embodiments, between 0.2 and 1.2 molar equivalent of excess free fatty acid is added to the reaction mixture. In another embodiment, approximately 1.2 molar equivalent of excess free fatty acid is added to the reaction mixture.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: December 31, 2019
    Assignee: QAAM PHARMACEUTICALS, LLC
    Inventors: Steven A. Rich, Emerich Eisenreich, Xuejun Karl Liu, Bingidimi Itute Mobele, Satish Goud Puppali
  • Publication number: 20180179156
    Abstract: Novel glycopyrronium fatty acid salts have been developed. Bi-phasic reaction conditions enable the desired counterion exchange reactions between glycopyrronium bromide and fatty acid salts of alkali metals and alkaline earth metals in methods to form glycopyrronium fatty acid salts. In preferred embodiments, an excess of the free fatty acid in the reaction mixture stabilizes the glycopyrronium fatty acid salt and reduces the formation of the impurity, Acid A. In some preferred embodiments, between 0.2 and 1.2 molar equivalent of excess free fatty acid is added to the reaction mixture. In another embodiment, approximately 1.2 molar equivalent of excess free fatty acid is added to the reaction mixture.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 28, 2018
    Inventors: Steven A. Rich, Emerich Eisenreich, Xuejun Karl Liu, Bingidimi Itute Mobele, Satish Goud Puppali